Skip to main content

Table 2 Results of Cox regression analysis

From: Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

Disease-free survival variables   Univariable analysis Multivariable analysis
  HR (95% CI) p Value HR (95% CI) p Value
 Tumor size < 4 cm 1 0.6 1 0.2
≥ 4 cm 1.35 (0.43 to 4.19) 0.43 (0.09 to 1.94)
 Nuclear grade 1/2 1 0.9 1 0.06
3 1 (0.28 to 3.56) 0.15 (0.02 to 1.13)
 ER + 1 0.03 1 0.03
3.72 (1.12 to 12.3) 7.53 (1.17 to 48.33)
 Nodal involvement 1 0.09 1 0.4
+ 5.75 (0.74 to 44.2) 2.25 (0.25 to 19.9)
 FMISO-TBR < 1.48 1 0.002 1 0.005
≥ 1.48 5.72 (1.83 to 17.82) 11.35 (2.07 to 62.23)
 Chemotherapy   1 0.9 N/A
+ 368,675.3 (5.3E-168 to 25.4E + 177)
Overall survival variables   Univariable analysis Multivariable analysis
  HR (95% CI) p Value HR (95% CI) p Value
 Tumor size < 4 cm 1 0.6 1 0.7
≥ 4 cm 1.45 (0.29 to 7.15) 0.71 (0.1 to 4.71)
 Nuclear grade 1/2 1 0.9 1 0.2
3 1.09 (1.18 to 6.57) 0.21 (0.01 to 2.82)
 ER + 1 0.2 1 0.1
3.03 (0.55 to 16.5) 10.24 (0.57 to 181.96)
 Nodal involvement 1 0.9 1 0.9
+ 411,595.95 (9.7E-202 to 1.74E + 210) 141,679.29 (7.17E-223 to 27.97E + 231)
 FMISO-TBR < 1.48 1 0.06 1 0.1
≥ 1.48 4.43 (0.88 to 22.17) 7.59 (0.63 to 90.68)
 Chemotherapy   1 0.9 N/A
+ 122,960.7 (6.7E-167 to 222.6E + 174)
  1. Abbreviations: FMISO 18F-fluoromisonidazole, ER Estrogen receptor, TBR Tissue-to-blood ratio